PURPOSE: Expression of CD44 and its variants has been shown to be relevant to tumor progression in various human malignancies. We evaluated the expression of CD44v6 in the primary lesions of stage I non-small cell lung cancer (NSCLC) and correlated the expression level to its prognosis. METHODS: The expression of CD44v6, measured by immunohistochemistry, was assessed in the tumor specimens from 190 patients with stage I NSCLC. Each slide was assigned a score: the average of the score of tumor cells staining multiplied by the score of staining intensity. And depending on the cut-off score based on receiver operating characteristic (ROC) curve analysis, the CD44v6 expression was categorized into high- and low-level groups, which were then correlated directly with the clinical outcomes. RESULTS: The high expression of CD44v6 was detected more frequently in the squamous cell carcinoma (38 of 71 patients, 53.5%) than in the other types of carcinoma (p < 0.05). The Kaplan-Meier survival curves showed that high level expression of CD44v6 indicated a better post-operative survival (p = 0.006), especially for stage IB disease (p = 0.049) and squamous cell carcinoma (p = 0.029). The multivariate analysis also confirmed that the expression of CD44v6 was an independent prognostic indicator (p = 0.011). CONCLUSIONS: CD44v6 might be correlated with histogenesis of NSCLC, and its decreased expression may be an adverse prognostic indicator for the patients with stage I NSCLC, especially for those with stage IB diseases. Patients of this subgroup might need adjuvant therapy additionally.
PURPOSE: Expression of CD44 and its variants has been shown to be relevant to tumor progression in various humanmalignancies. We evaluated the expression of CD44v6 in the primary lesions of stage I non-small cell lung cancer (NSCLC) and correlated the expression level to its prognosis. METHODS: The expression of CD44v6, measured by immunohistochemistry, was assessed in the tumor specimens from 190 patients with stage I NSCLC. Each slide was assigned a score: the average of the score of tumor cells staining multiplied by the score of staining intensity. And depending on the cut-off score based on receiver operating characteristic (ROC) curve analysis, the CD44v6 expression was categorized into high- and low-level groups, which were then correlated directly with the clinical outcomes. RESULTS: The high expression of CD44v6 was detected more frequently in the squamous cell carcinoma (38 of 71 patients, 53.5%) than in the other types of carcinoma (p < 0.05). The Kaplan-Meier survival curves showed that high level expression of CD44v6 indicated a better post-operative survival (p = 0.006), especially for stage IB disease (p = 0.049) and squamous cell carcinoma (p = 0.029). The multivariate analysis also confirmed that the expression of CD44v6 was an independent prognostic indicator (p = 0.011). CONCLUSIONS: CD44v6 might be correlated with histogenesis of NSCLC, and its decreased expression may be an adverse prognostic indicator for the patients with stage I NSCLC, especially for those with stage IB diseases. Patients of this subgroup might need adjuvant therapy additionally.
Authors: A Wimmel; M Schilli; U Kaiser; K Havemann; A Ramaswamy; D Branscheid; E Kogan; M Schuermann Journal: Lung Cancer Date: 1997-03 Impact factor: 5.705
Authors: Paul G Daft; Kaiyu Yuan; Jason M Warram; Michael J Klein; Gene P Siegal; Majd Zayzafoon Journal: Mol Cancer Res Date: 2013-01-30 Impact factor: 5.852
Authors: Yoon Ho Ko; Hye Sung Won; Eun Kyoung Jeon; Sook Hee Hong; Sang Young Roh; Young Seon Hong; Jae Ho Byun; Chan-Kwon Jung; Jin Hyoung Kang Journal: BMC Cancer Date: 2011-08-07 Impact factor: 4.430
Authors: Emily Van de Laar; Monica Clifford; Stefan Hasenoeder; Bo Ram Kim; Dennis Wang; Sharon Lee; Josh Paterson; Nancy M Vu; Thomas K Waddell; Shaf Keshavjee; Ming-Sound Tsao; Laurie Ailles; Nadeem Moghal Journal: Respir Res Date: 2014-12-31